Evidence map›Paper›PMID 26842469›Full record

ArticleJournal of virology2016

Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection.

Sara Gianella, Christy M Anderson, Susanna R Var, Michelli F Oliveira, Steven M Lada, Milenka V Vargas, Marta Massanella, Susan J Little, Douglas D Richman, Matthew C Strain and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 66 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  5. Review
  6. Observational
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Sex Differences in Human Immunodeficiency Virus Persistence and Reservoir Size During Aging.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Sara GianellaUniversity of California, San Diego, La Jolla, California, USA gianella@ucsd.edu.
Christy M AndersonUniversity of California, San Diego, La Jolla, California, USA.
Susanna R VarUniversity of California, San Diego, La Jolla, California, USA.
Michelli F OliveiraUniversity of California, San Diego, La Jolla, California, USA.
Steven M LadaUniversity of California, San Diego, La Jolla, California, USA.
Milenka V VargasUniversity of California, San Diego, La Jolla, California, USA.
Marta MassanellaUniversity of California, San Diego, La Jolla, California, USA.ORCID http://orcid.org/0000-0002-3326-151X
Susan J LittleUniversity of California, San Diego, La Jolla, California, USA.
Douglas D RichmanUniversity of California, San Diego, La Jolla, California, USA.
Matthew C StrainUniversity of California, San Diego, La Jolla, California, USA.
Josué Pérez-SantiagoUniversity of California, San Diego, La Jolla, California, USA.
Davey M SmithUniversity of California, San Diego, La Jolla, California, USA.
University of California San Diego · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAVID J MOORE · 2001 to 2026
$50.4M
Using NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VERDIN, ERIC M. · 2011 to 2015
$39.5M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
San Diego Clinical and Translational Research InstituteUL1TR000100 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2012 to 2015
$19.7M
HOPE Training GrantT32AI007384 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sara Gianella Weibel, Scott L Letendre · 1990 to 2026
$9.7M
Interdisciplinary Research Fellowship in NeuroAIDSR25MH081482 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARIANA CHERNER · 2007 to 2026
$5.2M
Molecular Epidemiology for HIV Prevention for Drug Users and Other Risk Groups DP1DA034978 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, DAVID MITCHELL · 2012 to 2016
$4.1M
NCATS NIH HHS UL1 TR000100NCATS NIH HHS UL1TR000100NIAID NIH HHS 5UM1AI068636-09NIAID NIH HHS AI007384NIAID NIH HHS AI036214NIAID NIH HHS AI100665NIAID NIH HHS K24 AI100665NIAID NIH HHS P30 AI027763NIAID NIH HHS P30-AI027763NIAID NIH HHS P30 AI036214NIAID NIH HHS R24 AI106039NIAID NIH HHS R24AI106039NIAID NIH HHS T32 AI007384NIAID NIH HHS U19 AI096113NIAID NIH HHS UM1 AI068636NIDA NIH HHS DA034978NIDA NIH HHS DP1 DA034978NIMH NIH HHS MH097520NIMH NIH HHS R01 MH097520NIMH NIH HHS R01 MH101012NIMH NIH HHS R25 MH081482
6 · The paper itself

Abstract

unlabelledAsymptomatic replication of human herpesviruses (HHV) is frequent in HIV-infected men and is associated with increased T-cell activation and HIV disease progression. We hypothesized that the presence of replication of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) (the most frequently detected HHV) might influence HIV DNA decay during antiretroviral therapy (ART). We investigated 607 peripheral blood mononuclear cell (PBMC) samples from 107 CMV-seropositive, HIV-infected men who have sex with men, who started ART within a median of 3 months from their estimated date of infection (EDI) and were monitored for a median of 19 months thereafter. Levels of HIV, CMV, and EBV DNA and cellular HIV RNA were measured by droplet digital PCR (ddPCR) for each time point. Using a general linear mixed-effect regression model, we evaluated associations between the presence of detectable CMV DNA and EBV DNA levels and HIV DNA decay and cellular HIV RNA levels, while adjusting for peak HIV RNA, nadir CD4(+)count, CD4/CD8 ratio, CMV IgG levels, time from EDI to ART initiation, time from ART initiation to virologic suppression, detectable CMV DNA pre-ART, and age. The presence of intermittent CMV DNA in PBMC during ART was significantly associated with slower decay of HIV DNA (P= 0.011) but not with increased cellular HIV RNA transcription or more detectable 2-long terminal repeat circles. Higher levels of EBV DNA were also associated with higher levels of HIV DNA (P< 0.001) and increased unspliced cellular HIV RNA transcription (P= 0.010). These observations suggest that replication of HHV may help maintain a larger HIV DNA reservoir, but the underlying mechanisms remain unclear. IMPORTANCE: Over three-fourths of HIV-infected men have at least one actively replicating human herpesvirus (HHV) in their mucosal secretions at any one time. Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are the most common, and although it is often asymptomatic, such CMV and EBV replication is associated with higher levels of immune activation and HIV disease progression. We hypothesized that HHV-associated activation of HIV-infected CD4(+)T cells might lead to increased HIV DNA. This study found that detectable CMV in blood cells of HIV-infected men was associated with slower decay of HIV DNA even during antiretroviral therapy (ART) that was started during early HIV infection. Similarly, levels of EBV DNA were associated with higher levels of HIV DNA during ART. If this observation points to a causal pathway, interventions that control CMV and EBV replication may be able to reduce the HIV reservoir, which might be relevant to current HIV cure efforts.

Indexed as

Virus ReplicationAdultAnti-HIV AgentsCytomegalovirusDNA, ViralHerpesvirus 4, HumanHIV-1HIV InfectionsHumansLeukocytes, MononuclearMaleRNA, ViralTime FactorsAnti-HIV AgentsDNA, ViralRNA, Viral

Identifiers

PMID26842469
PMCPMC4810527
OpenAlexW2317435049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.